AVALO THERAPEUTICS
Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
AVALO THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.avalotx.com
Total Employee:
11+
Status:
Active
Total Funding:
162.1 M USD
Technology used in webpage:
Euro COVID-19 Amazon Frankfurt Region
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Novelion Therapeutics
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Arch Oncology
Arch Oncology is a venture-stage biopharmaceutical company.
Current Advisors List
Board_member
2024-03-01
Board_member
2022-08-01
Current Employees Featured
John Boland Vice President, Clinical Operations @ Avalo Therapeutics
Vice President, Clinical Operations
2017-11-01
Michael Cola Chief Executive Officer, Chairman of the Board @ Avalo Therapeutics
Chief Executive Officer, Chairman of the Board
Garry Neil President & Chief Executive Officer @ Avalo Therapeutics
President & Chief Executive Officer
2022-02-01
Stephen Smolinski Chief Commercial Officer @ Avalo Therapeutics
Chief Commercial Officer
2022-01-03
Isaac Blech Founder & Vice Chairman @ Avalo Therapeutics
Founder & Vice Chairman
Paul Varki Chief Legal Officer @ Avalo Therapeutics
Chief Legal Officer
2024-06-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-27 | AlmataBio | AlmataBio acquired by Avalo Therapeutics | 15 M USD |
Investors List
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Avalo Therapeutics
BVF Partners
BVF Partners investment in Post-IPO Equity - Avalo Therapeutics
Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management investment in Post-IPO Equity - Avalo Therapeutics
Commodore Capital
Commodore Capital investment in Post-IPO Equity - Avalo Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Avalo Therapeutics
OrbiMed
OrbiMed investment in Post-IPO Equity - Avalo Therapeutics
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Avalo Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-06-24 | Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer |
| 2022-01-11 | Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer |
Official Site Inspections
http://www.avalotx.com Semrush global rank: 1.31 M Semrush visits lastest month: 20.39 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Avalo Therapeutics"
About :: Avalo Therapeutics, Inc. (AVTX)
About Us. Avalo is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory …See details»
Company Information :: Avalo Therapeutics, Inc. (AVTX)
Company Information Company Profile. Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL …See details»
Profile :: Avalo Therapeutics, Inc. (AVTX) - ir.avalotx.com
Pennsylvania Headquarters 1500 Liberty Ridge Drive Suite 321 Wayne, PA 19087 . Telephone: 610-254-4201. Email: info@avalotx.comSee details»
Avalo Therapeutics - Crunchbase Company Profile
Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.See details»
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement …
Mar 27, 2024 Management and Organization ... For more information about Avalo, please visit www.avalotx.com. About AlmataBio, Inc. AlmataBio, Inc. was formed in April 2023 and its …See details»
Patient Advocacy :: Avalo Therapeutics, Inc. (AVTX)
To ensure that our engagement and interactions with advocacy organizations respect the independence of all partners and are built on integrity and trust, Avalo Therapeutics aligns with …See details»
Avalo Therapeutics - Overview, News & Similar companies
Jul 9, 2024 Avalo Therapeutics contact info: Phone number: (410) 522-8707 Website: www.avalotx.com What does Avalo Therapeutics do? Founded in 2011, formally Cerecor, …See details»
AVTX-009 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Originator Organization. Eli Lilly & Co. AlmataBio, Inc. Active Organization. Avalo Therapeutics, Inc. Inactive Organization-Drug Highest Phase Phase 2. ... please visit …See details»
Avalo Therapeutics, Inc. (AVTX) - Yahoo Finance
Find the latest Avalo Therapeutics, Inc. (AVTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Avalo Therapeutics Announces Appointment of Paul Varki as Chief …
Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion …See details»
Avalo Acquires Anti-IL-1β mAb and Announces Private ... - Stock …
Mar 27, 2024 Management and Organization ... For more information about Avalo, please visit www.avalotx.com. About AlmataBio, Inc. AlmataBio, Inc. was formed in April 2023 and its …See details»
Patients and Families :: Avalo Therapeutics, Inc. (AVTX)
If you are a patient or family advocate and would like to engage in a conversation, we invite you to contact us* at advocacy@avalotx.com. *By providing your information, you agree to allow …See details»
Avalo Therapeutics, Inc. Announces Corporate Name Change from …
Sgreenway@avalotx.com 610-522-6200. For media inquiries. Robert Stanislaro or Helen O’Gorman FTI Consulting robert.stanislaro@fticonsulting.com …See details»
AVTX Stock Price Quote | Morningstar
Nov 21, 2024 See the latest Avalo Therapeutics Inc stock price (AVTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Apr 2, 2024 For more information about Avalo, please visit www.avalotx.com. Forward-Looking Statements This press release may include forward-looking statements made pursuant to the …See details»
Access to Investigational Therapies - Avalo Therapeutics, Inc.
Treating physicians interested in potential access to investigational products may request more information by contacting Avalo via email at expandedaccess@avalotx.com. Please note that …See details»
Avalo Therapeutics First Quarter 2022 Financial Results and …
May 5, 2022 “The first quarter has been highly productive for the Avalo Therapeutics team. We executed our pipeline prioritization plan and right-sized the organization needed to deliver …See details»
AVTX-008 - Drug Targets, Indications, Patents - Synapse - Patsnap
Originator Organization. Avalo Therapeutics, Inc. Active Organization-Inactive Organization. Avalo Therapeutics, Inc. Drug Highest Phase Discontinued Preclinical. First ... please visit …See details»
Pipeline - Avalo Therapeutics, Inc. (AVTX)
Targeted Therapies. Our pipeline emphasizes high value potential best-in-class biologics focused on dysregulated inflammation.See details»